Opexa Therapeutics (OPXA) +305% premarket on news it could be awarded up to $225M in a...

|About: Opexa Therapeutics, Inc. (OPXA)|By:, SA News Editor

Opexa Therapeutics (OPXA) +305% premarket on news it could be awarded up to $225M in a commercialization deal struck with Merck Serono for its multiple sclerosis therapy Tcelna. OPXA's lead product candidate is in Phase IIb trials in patients with secondary progressive MS, and has received FDA fast-track designation. Serono gains global development and commercial rights to Tcelna.